Vicki L. Ellingrod
Vicki L. Ellingrod
John Gideon Searle Professor of Clincal and Translational Pharmacy
Dirección de correo verificada de
Citado por
Citado por
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, K Shimoda, ...
Clinical pharmacology and therapeutics 102 (1), 37, 2017
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
JK Hicks, JJ Swen, CF Thorn, K Sangkuhl, ED Kharasch, VL Ellingrod, ...
Clinical Pharmacology & Therapeutics 93 (5), 402-408, 2013
Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants
AM Weissman, BT Levy, AJ Hartz, S Bentler, M Donohue, VL Ellingrod, ...
American Journal of Psychiatry 161 (6), 1066-1078, 2004
Antipsychotic‐induced hyperprolactinemia
JR Bostwick, SK Guthrie, VL Ellingrod
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29 (1 …, 2009
Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort
SA Flowers, SJ Evans, KM Ward, MG McInnis, VL Ellingrod
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (3 …, 2017
Weight gain associated with the− 759C/T polymorphism of the 5HT2C receptor and olanzapine
VL Ellingrod, PJ Perry, JC Ringold, BC Lund, K Bever‐Stille, F Fleming, ...
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 134 …, 2005
Psychosexual effects of three doses of testosterone cycling in normal men
WR Yates, PJ Perry, J MacIndoe, T Holman, V Ellingrod
Biological psychiatry 45 (3), 254-260, 1999
Clozapine‐induced weight gain associated with the 5HT2C receptor− 759C/T polymorphism
DD Miller, VL Ellingrod, TL Holman, PF Buckley, S Arndt
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 133 …, 2005
Venlafaxine: a heterocyclic antidepressant
VL Ellingrod, PJ Perry
American Journal of Health-System Pharmacy 51 (24), 3033-3046, 1994
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population
MJ Bly, SF Taylor, G Dalack, R Pop‐Busui, KJ Burghardt, SJ Evans, ...
Bipolar disorders 16 (3), 277-288, 2014
Serotonin 2A− 1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects
JR Bishop, J Moline, VL Ellingrod, SK Schultz, AH Clayton
Neuropsychopharmacology 31 (10), 2281-2288, 2006
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer
M O’Malley, AN King, M Conte, VL Ellingrod, N Ramnath
Journal of thoracic oncology 9 (7), 917-926, 2014
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C …
VL Ellingrod, DD Miller, SF Taylor, J Moline, T Holman, J Kerr
Schizophrenia research 98 (1-3), 47-54, 2008
Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers
J G Fiedorowicz, D Del Miller, J R Bishop, C A Calarge, V L Ellingrod, ...
Current psychiatry reviews 8 (1), 25-36, 2012
Variants of the dopamine D2 receptor and risperidone-induced hyperprolactinemia in children and adolescents
CA Calarge, VL Ellingrod, L Acion, DD Miller, J Moline, MJ Tansey, ...
Pharmacogenetics and genomics 19 (5), 373, 2009
C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects
DI Min, VL Ellingrod
Therapeutic drug monitoring 24 (3), 400-404, 2002
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.
VL Ellingrod, JR Bishop, J Moline, YC Lin, DD Miller
Psychopharmacology bulletin 40 (1), 57-62, 2007
Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics
VL Ellingrod, SF Taylor, G Dalack, TB Grove, MJ Bly, RD Brook, ...
Journal of clinical psychopharmacology 32 (2), 261, 2012
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment
JR Bishop, VL Ellingrod, J Moline, D Miller
Schizophrenia research 77 (2-3), 253-260, 2005
CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects 1
DI Min, VL Ellingrod, S Marsh, H McLeod
Therapeutic drug monitoring 26 (5), 524-528, 2004
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20